<DOC>
	<DOC>NCT00135317</DOC>
	<brief_summary>The study is designed to assess if the addition of intravenous (IV) iron to 500 mcg every 3 week (Q3W) darbepoetin alfa treatment enhances response as compared to the standard practice (oral iron or no iron administration).</brief_summary>
	<brief_title>AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects with nonmyeloid malignancy (chronic myeloid leukemia [CML], acute leukemia [acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL)], hairy cell leukemia, Burkitt's lymphoma and lymphoblastic lymphoma are specifically excluded) Planned to receive at least 8 weeks of cyclic cytotoxic chemotherapy regardless of schedule (chemotherapy may already be ongoing at time of screening) Hemoglobin concentration less than 11 g/dL within 24 hours before randomization Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 Known (documented in medical records) history of seizure disorder (subjects with a previous history of seizure disorders will be eligible for the study, if they have had no evidence of seizure activity, and have not been taking antiseizure medication for the previous 5 years) Known (documented in medical records) history of thromboembolism Known primary hematologic disorder which could cause anemia other than a nonmyeloid malignancy (e.g., sickle cell anemia, thalassemia) Radiotherapy within 4 weeks before randomization in which the radiation is administered to greater than 25% of the marrow Unstable or uncontrolled disease/condition, related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension and/or unstable cardiac arrhythmia) Chronic inflammatory disease that is not stable (e.g., rheumatoid arthritis, Crohn's disease, peptic ulcer, ulcerative disease, etc) Inadequate renal and/or liver function Received any red blood cell transfusion within 14 days before randomization or any planned red blood cell transfusion between randomization and study day 1 Received any erythropoietic therapy within 4 weeks before randomization or any planned erythropoietic therapy between randomization and study day 1 Known sensitivity to iron administration Subject of reproductive potential is evidently pregnant (e.g., positive serum HCG test) or is breast feeding Subject of reproductive potential who is not using adequate contraceptive precautions Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>oncology</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>AranespÂ®</keyword>
	<keyword>Amgen</keyword>
	<keyword>Non-myeloid malignancy</keyword>
</DOC>